新南威尔士州的数据链接研究揭示了HCC死亡风险的转变:是时候采取更广泛的战略了
Salim Maher1, Alamgir Kabir2, Jason Behary1
1Gastroenterology and Hepatology Department, St George Hospital, Sydney, NSW, Australia; School of Clinical Medicine, St George and Sutherland Clinical Campus, UNSW Sydney, NSW, Australia.
Cancer epidemiology
|November 1, 2024
概括
澳大利亚的肝细胞癌 (HCC) 死亡率在澳大利亚出生的人群和社会经济地位较低的人群中较高. 这些因素,以及年龄和酒精使用,显著影响生存率,突出了护理方面的差异.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 公共卫生 公共卫生
背景情况:
- 肝细胞癌 (HCC) 是一个重要的全球健康问题.
- 了解死亡率决定因素对于有针对性的干预至关重要.
研究的目的:
- 调查影响澳大利亚新南威尔士州 (NSW) HCC死亡率的社会人口和临床因素.
- 根据社会经济地位 (SES) 和其他关键变量,识别HCC生存率的差异.
主要方法:
- 一项为期15年的回顾性研究 (2001-2015年) 使用链接的健康和癌症登记数据.
- 对5454例HCC病例的分析,评估与HCC相关的死亡率和所有原因的死亡率.
- 多变量考克斯回归分析,包括基于位置的SES (SEIFA) 和临床因素.
主要成果:
- 在导致HCC的慢性肝病中,非病毒性原因占主导地位.
- 较高的HCC死亡率与较低的SES (SEIFA五分位数2-4与5) 相关,年龄较大 (≥65),男性性别和澳大利亚出生.
- 酒精使用并发症,诊断时的转移性疾病和缺乏手术显著增加了死亡风险.
结论:
- 非病毒性HCC在新南威尔士州比病毒相关的HCC更为普遍.
- 澳大利亚出生的个人和SES较低的人面临着最大的HCC死亡风险.
- 解决这些差异对于有效的预防和资源分配至关重要.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
222
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
